TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Physical Therapy on Pelvic Floor Symptoms and Quality of Life in Postpartum Women Following Severe Perineal Trauma: a Randomized Controlled Trial
Brief Summary: Our primary objective is to determine if physical therapy (PT) and behavioral therapy (BT) in the post-partum period after a vaginal delivery complicated by genital trauma help to improve a woman's quality of life, specifically in regard to anal incontinence. To be able to study this, the investigators need to know how well the muscles of a woman's pelvic floor function after a vaginal delivery and this requires measuring their strength during a pelvic exam. At present, there are no studies that have looked at whether the intervention of PT/BT improves a woman's anal incontinence quality of life after sustaining genital trauma during vaginal deliveries


Options:
A: Arm Label: Physical & Behavioral Therapy Group; Type: EXPERIMENTAL; Interventions: Behavioral: Physical Therapy (PT) and Behavioral Therapy (BT) | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Physical Therapy (PT) and Behavioral Therapy (BT); Assigned to Arm(s): Physical & Behavioral Therapy Group
B: Arm Label: Behavioral Training; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral training | Arm Label: Drug Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxybutynin chloride, extended-release | Intervention Type: BEHAVIORAL; Name: Behavioral training; Assigned to Arm(s): Behavioral Training | Intervention Type: DRUG; Name: Oxybutynin chloride, extended-release; Assigned to Arm(s): Drug Therapy
C: Arm Label: Rééducation; Type: EXPERIMENTAL; Interventions: Other: Pelvic floor muscle training with physiotherapist, Other: Written information about kegel exercises | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: Written information about kegel exercises | Intervention Type: OTHER; Name: Pelvic floor muscle training with physiotherapist; Assigned to Arm(s): Rééducation | Intervention Type: OTHER; Name: Written information about kegel exercises; Assigned to Arm(s): Control, Rééducation
D: Arm Label: Lifestyle Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle Intervention | Arm Label: Diabetes Support and Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Diabetes Support and Education | Intervention Type: BEHAVIORAL; Name: Lifestyle Intervention; Assigned to Arm(s): Lifestyle Intervention | Intervention Type: BEHAVIORAL; Name: Diabetes Support and Education; Assigned to Arm(s): Diabetes Support and Education

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Physical Therapy on Pelvic Floor Symptoms and Quality of Life in Postpartum Women Following Severe Perineal Trauma: a Randomized Controlled Trial
Brief Summary: Our primary objective is to determine if physical therapy (PT) and behavioral therapy (BT) in the post-partum period after a vaginal delivery complicated by genital trauma help to improve a woman's quality of life, specifically in regard to anal incontinence. To be able to study this, the investigators need to know how well the muscles of a woman's pelvic floor function after a vaginal delivery and this requires measuring their strength during a pelvic exam. At present, there are no studies that have looked at whether the intervention of PT/BT improves a woman's anal incontinence quality of life after sustaining genital trauma during vaginal deliveries


Options:
A: Arm Label: G1; Type: EXPERIMENTAL; Interventions: Procedure: Pregnants for receive the physical therapy guide | Intervention Type: PROCEDURE; Name: Pregnants for receive the physical therapy guide; Assigned to Arm(s): G1
B: Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: Educational Workshop | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Educational Workshop; Assigned to Arm(s): Intervention
C: Arm Label: Physical & Behavioral Therapy Group; Type: EXPERIMENTAL; Interventions: Behavioral: Physical Therapy (PT) and Behavioral Therapy (BT) | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Physical Therapy (PT) and Behavioral Therapy (BT); Assigned to Arm(s): Physical & Behavioral Therapy Group
D: Arm Label: Exercice; Type: OTHER; Interventions: Behavioral: preparation of the delivery | Arm Label: non-exercice; Type: OTHER; Interventions: Behavioral: preparation of the delivery | Intervention Type: BEHAVIORAL; Name: preparation of the delivery; Assigned to Arm(s): Exercice, non-exercice

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Oxytocin Antagonist in Patients With Repeated Failure of Implantation. A Prospective Randomized Placebo-controlled Double-blind Study.
Brief Summary: In this study the investigators compare the usual way of embryo transfer (without medication) with an embryo transfer while administering oxytocine antagonist. This to improve implantation and increase the pregnancy rate.


Options:
A: Arm Label: Endometrial injury group; Type: EXPERIMENTAL; Interventions: Procedure: Endometrial injury | Arm Label: Control group; Type: SHAM_COMPARATOR; Interventions: Procedure: Control group | Intervention Type: PROCEDURE; Name: Endometrial injury; Assigned to Arm(s): Endometrial injury group | Intervention Type: PROCEDURE; Name: Control group; Assigned to Arm(s): Control group
B: Arm Label: local ingury; Type: ACTIVE_COMPARATOR; Interventions: Procedure: local injury | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: local injury; Assigned to Arm(s): local ingury
C: Arm Label: Atosiban; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atosiban | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Atosiban; Assigned to Arm(s): Atosiban | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
D: Arm Label: Atosiban used before embryo transfer; Type: EXPERIMENTAL; Interventions: Drug: Atosiban | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Atosiban; Assigned to Arm(s): Atosiban used before embryo transfer

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Oxytocin Antagonist in Patients With Repeated Failure of Implantation. A Prospective Randomized Placebo-controlled Double-blind Study.
Brief Summary: In this study the investigators compare the usual way of embryo transfer (without medication) with an embryo transfer while administering oxytocine antagonist. This to improve implantation and increase the pregnancy rate.


Options:
A: Arm Label: atosiban; Type: EXPERIMENTAL; Interventions: Drug: atosiban | Arm Label: 0.9% salain; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% saline | Intervention Type: DRUG; Name: atosiban; Assigned to Arm(s): atosiban | Intervention Type: DRUG; Name: 0.9% saline; Assigned to Arm(s): 0.9% salain
B: Arm Label: Atosiban; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atosiban | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Atosiban; Assigned to Arm(s): Atosiban | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
C: Arm Label: M: Metformin P: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Metformin / Placebo treatment for 4 months | Intervention Type: DRUG; Name: Metformin / Placebo treatment for 4 months; Assigned to Arm(s): M: Metformin P: Placebo
D: Arm Label: Atosiban used before embryo transfer; Type: EXPERIMENTAL; Interventions: Drug: Atosiban | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Atosiban; Assigned to Arm(s): Atosiban used before embryo transfer

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Renal Sympathetic Denervation on Resistant Hypertension and Cardiovascular Hemodynamic in Comparison to Intensive Medical Therapy Utilizing Impedance Cardiography
Brief Summary: The purpose of this study is to demonstrate that Renal Sympathetic Denervation (RDN) improves the control of blood pressure (BP) in patients with treatment-resistant hypertension, as compared to intensive medical therapy (IMT) using hemodynamic parameters and then applying a predefined algorithm of drug selection (i.e. integrated hemodynamic management - IHM) during 6 months intensive treatment program (receiving antihypertensive care according to the 2007 ESH Guidelines). Working hypothesis: When it is possible to disrupt the sympatho-renal axis by RDN - BP reduction occurs to a greater extent and more rapidly than applying intensive medical therapy using IHM.


Options:
A: Arm Label: Denervation; Type: EXPERIMENTAL; Interventions: Device: Ardian Symplicity™ Catheter | Intervention Type: DEVICE; Name: Ardian Symplicity™ Catheter; Assigned to Arm(s): Denervation
B: Arm Label: Renal denervation; Type: EXPERIMENTAL; Interventions: Procedure: renal denervation and optimized medication regimen | Arm Label: optimized medication regimen; Type: OTHER; Interventions: Procedure: optimized medication regimen | Intervention Type: PROCEDURE; Name: renal denervation and optimized medication regimen; Assigned to Arm(s): Renal denervation | Intervention Type: PROCEDURE; Name: optimized medication regimen; Assigned to Arm(s): optimized medication regimen
C: Arm Label: Renal Denervation; Type: EXPERIMENTAL; Interventions: Device: Symplicity Spyral™ multi-electrode renal denervation system | Arm Label: Sham Procedure; Type: SHAM_COMPARATOR; Interventions: Procedure: Sham Procedure | Intervention Type: DEVICE; Name: Symplicity Spyral™ multi-electrode renal denervation system; Assigned to Arm(s): Renal Denervation | Intervention Type: PROCEDURE; Name: Sham Procedure; Assigned to Arm(s): Sham Procedure
D: Arm Label: group Co; Type: ACTIVE_COMPARATOR; Interventions: Device: The HOTMAN® System | Arm Label: group RDN; Type: ACTIVE_COMPARATOR; Interventions: Procedure: The SymplicityTM Renal Denervation System | Intervention Type: PROCEDURE; Name: The SymplicityTM Renal Denervation System; Assigned to Arm(s): group RDN | Intervention Type: DEVICE; Name: The HOTMAN® System; Assigned to Arm(s): group Co

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Renal Sympathetic Denervation on Resistant Hypertension and Cardiovascular Hemodynamic in Comparison to Intensive Medical Therapy Utilizing Impedance Cardiography
Brief Summary: The purpose of this study is to demonstrate that Renal Sympathetic Denervation (RDN) improves the control of blood pressure (BP) in patients with treatment-resistant hypertension, as compared to intensive medical therapy (IMT) using hemodynamic parameters and then applying a predefined algorithm of drug selection (i.e. integrated hemodynamic management - IHM) during 6 months intensive treatment program (receiving antihypertensive care according to the 2007 ESH Guidelines). Working hypothesis: When it is possible to disrupt the sympatho-renal axis by RDN - BP reduction occurs to a greater extent and more rapidly than applying intensive medical therapy using IHM.


Options:
A: Arm Label: Ultrasound Renal Denervation; Type: EXPERIMENTAL; Interventions: Device: The Paradise® Renal Denervation Ultrasound System | Arm Label: Sham Procedure; Type: SHAM_COMPARATOR; Interventions: Device: Sham Procedure | Intervention Type: DEVICE; Name: The Paradise® Renal Denervation Ultrasound System; Assigned to Arm(s): Ultrasound Renal Denervation | Intervention Type: DEVICE; Name: Sham Procedure; Assigned to Arm(s): Sham Procedure
B: Arm Label: Renal Denervation; Type: EXPERIMENTAL; Interventions: Device: Renal Denervation | Intervention Type: DEVICE; Name: Renal Denervation; Assigned to Arm(s): Renal Denervation
C: Arm Label: group Co; Type: ACTIVE_COMPARATOR; Interventions: Device: The HOTMAN® System | Arm Label: group RDN; Type: ACTIVE_COMPARATOR; Interventions: Procedure: The SymplicityTM Renal Denervation System | Intervention Type: PROCEDURE; Name: The SymplicityTM Renal Denervation System; Assigned to Arm(s): group RDN | Intervention Type: DEVICE; Name: The HOTMAN® System; Assigned to Arm(s): group Co
D: Arm Label: Renal denervation; Type: EXPERIMENTAL; Interventions: Procedure: renal denervation and optimized medication regimen | Arm Label: optimized medication regimen; Type: OTHER; Interventions: Procedure: optimized medication regimen | Intervention Type: PROCEDURE; Name: renal denervation and optimized medication regimen; Assigned to Arm(s): Renal denervation | Intervention Type: PROCEDURE; Name: optimized medication regimen; Assigned to Arm(s): optimized medication regimen

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Placebo-controlled, Study to Evaluate the Effects of GSK1278863A on Pulmonary Artery Pressure in Healthy Volunteers
Brief Summary: This protocol is designed to explore whether short-term therapy with GSK1278863 affects PASP under normoxic and hypoxic conditions in healthy volunteers. Healthy subjects will be evaluated using echocardiography to estimate PASP based on the velocity of the tricuspid regurgitant jet. Resting PASP will be assessed under normoxic (room air) conditions, as well as after 30 minutes' exposure to 15% O2 before, during, and after short-term treatment with GSK1278863.


Options:
A: Arm Label: GSK1278863 5mg; Type: EXPERIMENTAL; Interventions: Drug: GSK1278863 | Arm Label: GSK1278863 100mg; Type: EXPERIMENTAL; Interventions: Drug: GSK1278863 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: GSK1278863; Assigned to Arm(s): GSK1278863 100mg, GSK1278863 5mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: XRP0038 (NV1FGF); Assigned to Arm(s): N/A
C: Arm Label: BM-MNC; Type: EXPERIMENTAL; Interventions: Procedure: BM-MNC preparation | Arm Label: PB-MNC; Type: EXPERIMENTAL; Interventions: Procedure: PB-MNC preparation | Intervention Type: PROCEDURE; Name: BM-MNC preparation; Assigned to Arm(s): BM-MNC | Intervention Type: PROCEDURE; Name: PB-MNC preparation; Assigned to Arm(s): PB-MNC
D: Arm Label: GM-CSF; Type: EXPERIMENTAL; Interventions: Drug: Granulocyte-Macrophage Stimulating Factor (GM-CSF) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Granulocyte-Macrophage Stimulating Factor (GM-CSF); Assigned to Arm(s): GM-CSF | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-Label Randomized Phase III Trial of BMS-936558 (Nivolumab) Versus Docetaxel in Previously Treated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)
Brief Summary: The purpose of the study is to compare the overall survival of BMS-936558 (Nivolumab) as compared with Docetaxel in subjects with non-squamous cell non-small cell lung cancer (NSCLC) after failure of prior platinum-based chemotherapy


Options:
A: Arm Label: (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine); Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Cisplatin, Drug: Gemcitabine, Drug: Pemetrexed | Arm Label: Atezolizumab; Type: EXPERIMENTAL; Interventions: Drug: Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody | Intervention Type: DRUG; Name: Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody; Assigned to Arm(s): Atezolizumab | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine)
B: Arm Label: Module A; Type: EXPERIMENTAL; Interventions: Biological: Ipilimumab, Biological: Nivolumab, Drug: Carboplatin, Drug: Paclitaxel, Drug: Pemetrexed, Drug: Cisplatin | Arm Label: Module B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Paclitaxel, Drug: Pemetrexed, Drug: Cisplatin | Intervention Type: BIOLOGICAL; Name: Ipilimumab; Assigned to Arm(s): Module A | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Module A | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Module A, Module B | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Module A, Module B | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): Module A, Module B | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Module A, Module B
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Monotherapy (gemcitabine or vinorelbine) | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Paclitaxel + Carboplatin | Intervention Type: DRUG; Name: Paclitaxel + Carboplatin; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Monotherapy (gemcitabine or vinorelbine); Assigned to Arm(s): A
D: Arm Label: Arm A: Nivolumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab | Arm Label: Arm B: Docetaxel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Docetaxel | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Arm A: Nivolumab | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): Arm B: Docetaxel

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi Protocol Investigation to Compare the Effects of Intra-dialytic Exercise on Physiological Changes and Toxin Removal in Maintenance Hemodialysis Patients
Brief Summary: Hemodialysis is a life-saving treatment for end stage renal disease patients. The chief aims of hemodialysis are solute and fluid removal. Solute removal is associated with outcome of dialysis patients. Intra-dialytic exercise has been found to improve the toxin removal and it is suggested that exercise increases the cardiac output, thus increases the blood flow to lower extremities. This leads to increased toxin removal from low blood flow regions. On the other hand, exercise can possibly dilate the vasculature and decrease the compartmental resistance. In this study, the investigators aim to investigate the exercise induced physiological changes which enhances the toxin removal. This information combined with patient specific mathematical models will encourage clinicians to opt for Optimal intra-dialytic exercise protocol. On the other hand, Hemodiafiltration is widely accepted renal replacement therapy for improved toxin removal. Hence, we intend to compare the toxin removal outcome for standalone Hemodiafiltration and intra-dialytic exercise in conventional hemodialysis.


Options:
A: Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: activity group; Type: EXPERIMENTAL; Interventions: Device: Exercise training in addition to nutritional support | Intervention Type: DEVICE; Name: Exercise training in addition to nutritional support; Assigned to Arm(s): activity group
B: Arm Label: HD-Exercise-HDF; Type: EXPERIMENTAL; Interventions: Procedure: Intra-dialytic exercise | Intervention Type: PROCEDURE; Name: Intra-dialytic exercise; Assigned to Arm(s): HD-Exercise-HDF
C: Arm Label: Exercise training; Type: EXPERIMENTAL; Interventions: Other: Exercise training | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Exercise training; Assigned to Arm(s): Exercise training
D: Arm Label: Dopamine Agonist Group; Type: EXPERIMENTAL; Interventions: Other: Dopamine Agonist and Exercise | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Other: Dopamine Agonist and Exercise | Intervention Type: OTHER; Name: Dopamine Agonist and Exercise; Assigned to Arm(s): Dopamine Agonist Group, Placebo Group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase II Randomized Open Label Study of Neo-Adjuvant Degarelix vs. LHRH Agonist in Prostate Cancer Patients Prior to Radical Prostatectomy
Brief Summary: To assess the effect of neo-adjuvant GnRH antagonist, degarelix, versus LHRH agonist on intratumoral levels of androgens.


Options:
A: Arm Label: Degarelix; Type: EXPERIMENTAL; Interventions: Drug: Degarelix | Arm Label: Degarelix + Casodex; Type: EXPERIMENTAL; Interventions: Drug: Degarelix, Drug: Casodex | Arm Label: LHRH Agonist + Casodex; Type: ACTIVE_COMPARATOR; Interventions: Drug: Casodex, Drug: LHRH Agonist | Intervention Type: DRUG; Name: Degarelix; Assigned to Arm(s): Degarelix, Degarelix + Casodex | Intervention Type: DRUG; Name: Casodex; Assigned to Arm(s): Degarelix + Casodex, LHRH Agonist + Casodex | Intervention Type: DRUG; Name: LHRH Agonist; Assigned to Arm(s): LHRH Agonist + Casodex
B: Arm Label: Degarelix 240 mg/80 mg; Type: EXPERIMENTAL; Interventions: Drug: Degarelix | Arm Label: Goserelin (3.6 mg) + bicalutamide (50 mg); Type: ACTIVE_COMPARATOR; Interventions: Drug: Goserelin, Drug: Bicalutamide | Intervention Type: DRUG; Name: Degarelix; Assigned to Arm(s): Degarelix 240 mg/80 mg | Intervention Type: DRUG; Name: Goserelin; Assigned to Arm(s): Goserelin (3.6 mg) + bicalutamide (50 mg) | Intervention Type: DRUG; Name: Bicalutamide; Assigned to Arm(s): Goserelin (3.6 mg) + bicalutamide (50 mg)
C: Arm Label: ASP3550 PART 1 and PART 2; Type: EXPERIMENTAL; Interventions: Drug: degarelix | Arm Label: Goserelin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Goserelin | Intervention Type: DRUG; Name: degarelix; Assigned to Arm(s): ASP3550 PART 1 and PART 2 | Intervention Type: DRUG; Name: Goserelin; Assigned to Arm(s): Goserelin
D: Arm Label: Degarelix 240 mg / 80 mg; Type: EXPERIMENTAL; Interventions: Drug: Degarelix 240 mg / 80 mg | Intervention Type: DRUG; Name: Degarelix 240 mg / 80 mg; Assigned to Arm(s): Degarelix 240 mg / 80 mg

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomised Surgical Intervention Study Between Adenotonsillectomy and Adenotonsillotomy in Children With Obstructive Sleep Apnea Syndrome
Brief Summary: Non-inferiority hypothesis; adenotonsillotomy is equally good as adenotonsillectomy in treating obstructive sleep apnea syndrome (OSAS) in children after one, three and ten years.


Options:
A: Arm Label: Electrocautery tonsillectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Tonsillectomy, laser tonsillotomy, debrider tonsillotomy | Arm Label: Debrider tonsillotomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Tonsillectomy, laser tonsillotomy, debrider tonsillotomy | Arm Label: Laser tonsillotomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Tonsillectomy, laser tonsillotomy, debrider tonsillotomy | Intervention Type: PROCEDURE; Name: Tonsillectomy, laser tonsillotomy, debrider tonsillotomy; Assigned to Arm(s): Debrider tonsillotomy, Electrocautery tonsillectomy, Laser tonsillotomy
B: Arm Label: Adenotonsillectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Adenotonsillectomy | Arm Label: Adenotonsillotomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Adenotonsillotomy | Intervention Type: PROCEDURE; Name: Adenotonsillectomy; Assigned to Arm(s): Adenotonsillectomy | Intervention Type: PROCEDURE; Name: Adenotonsillotomy; Assigned to Arm(s): Adenotonsillotomy
C: Arm Label: 1; Type: NO_INTERVENTION; Interventions: Other: no intervention | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Tonsillectomy | Intervention Type: PROCEDURE; Name: Tonsillectomy; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: no intervention; Assigned to Arm(s): 1
D: Intervention Type: PROCEDURE; Name: (adeno)tonsillectomy; Assigned to Arm(s): N/A

Answer: B